Skip to main content

Advertisement

SpringerLink
Log in

Comparison of the intraocular pressure-lowering effect and safety of brimonidine/timolol fixed combination and 0.5 % timolol in normal-tension glaucoma patients

  • Clinical Investigation
  • Published:
Japanese Journal of Ophthalmology Aims and scope Submit manuscript

Abstract

Purpose

To compare the therapeutic efficacy and safety of brimonidine/timolol fixed-combination (BTFC) and 0.5 % timolol ophthalmic solution in normal-tension glaucoma (NTG) patients.

Methods

This was a multi-institution, randomized, active-controlled, open-label, parallel-group study. After a full ophthalmic and glaucoma examination, a total of 110 NTG patients—55 undergoing therapy with BTFC and 55 0.5 %, with timolol—participated in this study. Among them, 1 failed to meet the inclusion/exclusion criteria, 10 revoked their consent to participate in the study, 3 had adverse reactions, and 1 had a drug adherence rate of less than 70 %. Ultimately, a total of 95 patients—48 in the BTFC group and 47 in the 0.5 % timolol group—completed the study. The study visits took place at baseline and at 4 and 12 weeks. Diurnal IOP was measured at 9 a.m., 11 a.m., and 5 p.m. during the baseline visit and the visit at 12 weeks after eye-drop instillation. At each follow-up visit, compliance was assessed. Throughout the study, all adverse events were recorded and monitored by the investigators.

Results

The average difference in IOP change measured at 11 a.m. 12 weeks after administration between the two groups was 2.10 ± 2.59 mmHg. The BTFC group had a better IOP-lowering effect at all time points than did the 0.5 % timolol group. The ratio of patients whose average IOP had decreased by >20 % after 4 and 12 weeks was 50 and 56 % in the BTFC group, respectively, whereas it was 29.41 and 23.53 % in the 0.5 % timolol group, respectively (p = 0.034, <0.001).

Conclusions

BTFC has a superior IOP-lowering effect than 0.5 % timolol in NTG patients.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Iwase A, Suzuki Y, Araie M, Yamamoto T, Abe H, Shirato S, et al. Tajimi Study Group Japan Glaucoma Society. The prevalence of primary open-angle glaucoma in Japanese: the Tajimi study. Ophthalmology. 2004;111:1641–8.

    PubMed  Google Scholar 

  2. Kim CS, Seong GJ, Lee NH, Song KC. Prevalence of primary open-angle glaucoma in central South Korea: the Namil study. Ophthalmology. 2011;118:1024–30.

    Article  PubMed  Google Scholar 

  3. McMonnies CW. Intraocular pressure spikes in keratectasia, axial myopia, and glaucoma. Optom Vis Sci. 2008;85:1018–26.

    Article  PubMed  Google Scholar 

  4. Collaborative Normal-Tension Glaucoma Study Group. The effectiveness of intraocular pressure reduction in the treatment of normal-tension glaucoma. Am J Ophthalmol. 1998;126:498–505.

    Article  Google Scholar 

  5. Collaborative Normal-Tension Glaucoma Study Group. Comparison of glaucomatous progression between untreated patients with normal-tension glaucoma and patients with therapeutically reduced intraocular pressures. Am J Ophthalmol. 1998;126:487–97.

    Article  Google Scholar 

  6. Kim TW, Kim M, Lee EJ, Jeoung JW, Park KH. Intraocular pressure-lowering efficacy of dorzolamide/timolol fixed combination in normal-tension glaucoma. J Glaucoma. 2014;23:329–32.

    Article  PubMed  Google Scholar 

  7. Cho SW, Kim JM, Park KH, Choi CY. Effects of brimonidine 0.2%-timolol 0.5 % fixed-combination therapy for glaucoma. Jpn J Ophthalmol. 2010;54:407–13.

    Article  PubMed  CAS  Google Scholar 

  8. Shim SH, Kim JM, Choi CY, Kim CY. Diurnal intraocular pressure with bimatoprost/timolol fixed combination versus latanoprost/timolol fixed combination in healthy subjects. Korean J Ophthalmol. 2014;28:39–48.

    Article  PubMed  CAS  PubMed Central  Google Scholar 

  9. Budengeri P, Cheng JW, Cai JP, Wei RL. Efficacy and tolerability of fixed combination of brimonidine 0.2 %/timolol 0.5 % compared with fixed combination of dorzolamide 2 %/timolol 0.5 % in the treatment of patients with elevated intraocular pressure: a meta-analysis of randomized controlled trials. J Ocul Pharmacol Ther. 2013;29:474–9.

    Article  PubMed  CAS  Google Scholar 

  10. Frampton JE. Topical brimonidine 0.2%/timolol 0.5 % ophthalmic solution: in glaucoma and ocular hypertension. Drugs Aging. 2006;23:753–61.

    Article  PubMed  CAS  Google Scholar 

  11. der Valk Van, Webers CA, Lumley T, Hendrikse F, Prins MH, Schouten JS. A network meta-analysis combined direct and indirect comparisons between glaucoma drugs to rank effectiveness in lowering intraocular pressure. J Clin Epidemiol. 2009;62:1279–83.

    Article  PubMed  Google Scholar 

  12. Nixon DR, Yan DB, Chartrand JP, Piemontesi RL, Simonyi S, Hollander DA. Three-month, randomized, parallel-group comparison of brimonidine-timolol versus dorzolamide-timolol fixed-combination therapy. Curr Med Res Opin. 2009;25:1645–53.

    Article  PubMed  CAS  Google Scholar 

  13. García-Feijoó J, Sáenz-Francés F, Martínez-de-la-Casa JM, Méndez-Hernández C, Fernández-Vidal A, Calvo-González C, et al. Comparison of ocular hypotensive actions of fixed combinations of brimonidine/timolol and dorzolamide/timolol. Curr Med Res Opin. 2010;26:1599–606.

    Article  PubMed  Google Scholar 

  14. Sherwood MB, Craven ER, Chou C, DuBiner HB, Batoosingh AL, Schiffman RM, et al. Twice-daily 0.2 % brimonidine-0.5 % timolol fixed-combination therapy vs monotherapy with timolol or brimonidine in patients with glaucoma or ocular hypertension: a 12-month randomized trial. Arch Ophthalmol. 2006;124:1230–8.

    Article  PubMed  CAS  Google Scholar 

  15. Konstas AG, Katsimpris IE, Kaltsos K, Georgiadou I, Kordelou A, Nelson LA, et al. Twenty-four-hour efficacy of the brimonidine/timolol fixed combination versus therapy with the unfixed components. Eye (Lond). 2008;22:1391–7.

    Article  CAS  Google Scholar 

  16. Spaeth GL, Bernstein P, Caprioli J, Schiffman RM. Control of intraocular pressure and fluctuation with fixed-combination brimonidine-timolol versus brimonidine or timolol monotherapy. Am J Ophthalmol. 2011;151:93–9.

    Article  PubMed  CAS  Google Scholar 

  17. Chan K, Testa M, McCluskey P. Ocular comfort of combination glaucoma therapies: brimonidine 0.2%/timolol 0.5 % compared with dorzolamide 2%/timolol 0.5 %. J Ocul Pharmacol Ther. 2007;23:372–6.

    Article  PubMed  CAS  Google Scholar 

  18. Loon SC, Liew G, Fung A, Reid SE, Craig JC. Meta-analysis of randomized controlled trials comparing timolol with brimonidine in the treatment of glaucoma. Clin Exp Ophthalmol. 2008;36:281–9.

    Article  Google Scholar 

  19. Toris CB, Gleason ML, Camras CB, Yablonski ME. Effects of brimonidine on aqueous humor dynamics in human eyes. Arch Ophthalmol. 1995;113:1514–7.

    Article  PubMed  CAS  Google Scholar 

  20. Zimmerman TJ, Kaufman HE. Timolol: a beta-adrenergic blocking agent for the treatment of glaucoma. Arch Ophthalmol. 1977;95:601–4.

    Article  PubMed  CAS  Google Scholar 

  21. Tomita G, Araie M, Kitazawa Y, Tsukahara S. A three-year prospective, randomized and open comparison between latanoprost and timolol in Japanese normal-tension glaucoma patients. Eye (Lond). 2004;18:984–9.

    Article  CAS  Google Scholar 

  22. Oh JY, Park KH. The effect of latanoprost on intraocular pressure during 12 months of treatment for normal-tension glaucoma. Korean J Ophthalmol. 2005;19:297–301.

    Article  PubMed  Google Scholar 

  23. Suh MH, Park KH, Kim DM. Effect of travoprost on intraocular pressure during 12 months of treatment for normal-tension glaucoma. Jpn J Ophthalmol. 2009;53:18–23.

    Article  PubMed  Google Scholar 

  24. Kim MJ, Park KH, Kim CY, Jeoung JW, Kim SH. The distribution of intraocular pressure and associated systemic factors in a Korean population: the Korea National Health and Nutrition Examination Survey. Acta Ophthalmol. 2014;92:507–13.

    Article  Google Scholar 

  25. Craven ER, Walters TR, Williams R, Chou C, Cheetham JK. Schiffman R; Combigan Study Group. Brimonidine and timolol fixed-combination therapy versus monotherapy: a 3-month randomized trial in patients with glaucoma or ocular hypertension. J Ocul Pharmacol Ther. 2005;21:337–48.

    Article  PubMed  CAS  Google Scholar 

  26. Cheng JW, Cai JP, Wei RL. Meta-analysis of medical intervention for normal tension glaucoma. Ophthalmology. 2009;116:1243–9.

    Article  PubMed  Google Scholar 

  27. Rulo AH, Greve EL, Geijssen HC, Hoyng PF. Reduction of intraocular pressure with treatment of latanoprost once daily in patients with normal-pressure glaucoma. Ophthalmology. 1996;103:1276–82.

    Article  PubMed  CAS  Google Scholar 

  28. Quaranta L, Pizzolante T, Riva I, Haidich AB, Konstas AG, Stewart WC. Twenty-four-hour intraocular pressure and blood pressure levels with bimatoprost versus latanoprost in patients with normal-tension glaucoma. Br J Ophthalmol. 2008;92:1227–31.

    Article  PubMed  CAS  Google Scholar 

  29. Park KH, Simonyi S, Kim CY, Sohn YH, Kook MS. Bimatoprost 0.01 % in treatment-naïve patients with open-angle glaucoma or ocular hypertension: an observational study in the Korean clinical setting. BMC Ophthalmol. 2014;17(14):160.

    Article  Google Scholar 

  30. Motolko MA. Comparison of allergy rates in glaucoma patients receiving brimonidine 0.2 % monotherapy versus fixed-combination brimonidine 0.2%-timolol 0.5% therapy. Curr Med Res Opin. 2008;24:2663–7.

    Article  PubMed  CAS  Google Scholar 

  31. Osborne SA, Montgomery DM, Morris D, McKay IC. Alphagan allergy may increase the propensity for multiple eye-drop allergy. Eye (Lond). 2005;19:129–37.

    Article  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Ophthalmology, Kangbuk Samsung Hospital, Sungkyunkwan University School of Medicine, Seoul, Republic of Korea

    Joon Mo Kim

  2. Department of Ophthalmology, Seoul National University Bundang Hospital, Seoul National University College of Medicine, Seongnam, Republic of Korea

    Tae-Woo Kim

  3. Department of Ophthalmology, Yonsei University College of Medicine, Seoul, Republic of Korea

    Chan Yun Kim

  4. Department of Ophthalmology, Myung-Gok Eye Research Institute, Kim’s Eye Hospital, Konyang University College of Medicine, Seoul, Republic of Korea

    Hwang Ki Kim

  5. Department of Ophthalmology, Seoul National University College of Medicine, Seoul National University Hospital, Seoul, Republic of Korea

    Ki Ho Park

Authors
  1. Joon Mo Kim
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Tae-Woo Kim
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Chan Yun Kim
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Hwang Ki Kim
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Ki Ho Park
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Ki Ho Park.

Ethics declarations

J. M. Kim, Grant (Allergan); T. -W. Kim, Grant (Allergan); C. Y. Kim, Grant (Allergan); H. K. Kim, Grant (Allergan); K. H. Park, Grant (Allergan)

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Kim, J.M., Kim, TW., Kim, C.Y. et al. Comparison of the intraocular pressure-lowering effect and safety of brimonidine/timolol fixed combination and 0.5 % timolol in normal-tension glaucoma patients. Jpn J Ophthalmol 60, 20–26 (2016). https://doi.org/10.1007/s10384-015-0420-2

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s10384-015-0420-2

Keywords

Search

Navigation